CKD Bio Corp. (KRX:063160)

Market Cap	73.84B -42.5%
Revenue (ttm)	159.93B +3.6%
Net Income	-23.13B
EPS	-4,216.38
Shares Out	5.49M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,314
Open	13,540
Previous Close	13,540
Day's Range	12,870 - 13,540
52-Week Range	11,770 - 24,900
Beta	0.59
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About CKD Bio

CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 519
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 063160

Financial Performance

In 2022, CKD Bio's revenue was 156.04 billion, an increase of 9.70% compared to the previous year's 142.24 billion. Losses were -16.70 billion, 154.0% more than in 2021.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 13, 2026

Data Sources Report a data error